Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model

International Journal of Cancer

Volumn 132, Issue 8, 2013, Pages 1860-1867

  Ghosh, Subrata K ^a   Uchida, Masashi ^a   Yoo, Byunghee ^a   Ross, Alana W ^a   Gendler, Sandra J ^b   Gong, Jianlin ^c   Moore, Anna ^a   Medarova, Zdravka ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antigen downregulation; breast cancer; molecular imaging; target specific contrast agent; underglycosylated MUC 1 antigen

Indexed keywords

DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; MUCIN 1; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; UNDERGLYOCSYLATED MUCIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOLECULAR IMAGING; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR IMAGING; MUCIN-1;

EID: 84873990263     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27872     Document Type: Article

References (38)

1. Xing P, Tjandra J, Stacker S, et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol 1989; 67 (Part 3): 183-95.
2. Hayes D, Mesa-Tejada R, Papsidero L, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 1991; 9: 1113-23.
3. Perey L, Hayes D, Maimonis P, et al. Tumor-specific reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the D3 human breast carcinoma-associated antigen. Cancer Res 1992; 52: 2563-8.
4. Nacht M, Ferguson A, Zhang W, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999; 59: 5464-70.
5. Dede DS, Arslan C, Altundag K,. Serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of diagnosis. Med Oncol 2010; 27: 1429.
6. Park S, Ahn HK, Park LC, et al. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer. Oncology 2012; 82: 180-7.
7. McGuckin MA, Walsh MD, Hohn BG, et al. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 1995; 26: 432-9.
8. Croce MV, Colussi AG, Price MR, et al. Expression of tumour associated antigens in normal, benign and malignant human mammary epithelial tissue: a comparative immunohistochemical study. Anticancer Res 1997; 17: 4287-92.
9. Yonezawa S, Sato E,. Expression of mucin antigens in human cancers and its relationship with malignancy potential. Pathol Int 1997; 47: 813-30.
10. Cao Y, Blohm D, Ghadimi BM, et al. Mucins (MUC1 and MUC3) of gastrointestinal and breast epithelia reveal different and heterogeneous tumor-associated aberrations in glycosylation. J Histochem Cytochem 1997; 45: 1547-57.
11. Barratt-Boyes S,. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother 1996; 43: 142-51.
12. Schroeder JA, Masri AA, Adriance MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 2004; 23: 5739-47.
13. Mommers E, Leonhart A, Silvia, et al. Abberant expression of MUC1 mucin in ductal hyperplasia and ductal carcinoma in situ of teh breast. Int J Cancer 1999; 84: 466-9.
14. de Roos MA, van der Vegt B, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast. Histopathology 2007; 51: 227-38.
15. Al-azawi D, Kelly G, Myers E, et al. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC cancer 2006; 6: 220.
16. Hanson JM, BroweIl DA, Cunliffe WJ, et al. MUC1 expression in primary breast cancer: the effect of tamoxifen treatment. Breast Cancer Res Treat 2001; 67: 215-22.
17. Yuan Z, Wong S, Borrelli A, et al. Down-regulation of MUC1 in cancer cells inhibits cell migration by promoting E-cadherin/catenin complex formation. Biochem Biophys Res Commun 2007; 362: 740-6.
18. Shi FF, Gunn GR, Snyder LA, et al. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases. Vaccine 2007; 25: 3338-46.
19. Scholl S, Squiban P, Bizouarne N, et al. Metastatic breast tumour regression following treatment by a gene-modified vaccinia virus expressing MUC1 and IL-2. J Biomed Biotechnol 2003; 2003: 194-201.
20. Spicer A, Rowse G, Lidner T, et al. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995; 270: 30093-101.
21. Moore A, Medarova Z, Potthast A, et al. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004; 64: 1821-7.
22. Medarova Z, Pham W, Kim Y, et al. In vivo imaging of tumor response to therapy using a dual-modality imaging strategy. Int J Cancer 2006; 118: 2796-802.
23. Medarova Z, Rashkovetsky L, Pantazopoulos P, et al. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res 2009; 69: 1182-9.
24. Chen D, Xia J, Tanaka Y, et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003; 109: 300-7.
25. Harisinghani M, Barentsz J, Hahn P, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. New Engl J Med 2003; 348: 2491-9.
26. Heyn C, Bowen CV, Rutt BK, et al. Detection threshold of single SPIO-labeled cells with FIESTA. Magn Reson Med 2005; 53: 312-20.
27. Caravan P,. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev 2006; 35: 512-23.
28. Sosnovik DE, Nahrendorf M, Weissleder R,. Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol 2008; 103: 122-30.
29. Heyn C, Ronald JA, Mackenzie LT, et al. In vivo magnetic resonance imaging of single cells in mouse brain with optical validation. Magn Reson Med 2006; 55: 23-9.
30. Wagner S, Schnorr J, Pilgrimm H, et al. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol 2002; 37: 167-77.
31. Medarova Z, Kumar M, Ng S, et al. Multifunctional magnetic nanocarriers for image-tagged siRNA delivery to intact pancreatic islets. Transplantation 2008; 86: 1170-7.
32. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007; 13: 372-7.
33. Arbab AS, Frank JA,. Cellular MRI and its role in stem cell therapy. Regen Med 2008; 3: 199-215.
34. Grimm J, Potthast A, Wunder A, et al. Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Int J Cancer 2003; 106: 806-11.
35. Bayraktar S, Elsayegh N, Gutierrez Barrera AM, et al. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. Cancer 2012; 118: 1515-22.
36. Shin HJ, Baek HM, Ahn JH, et al. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS. NMR Biomed, in press.
37. Youk JH, Son EJ, Chung J, et al. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes. Eur Radiol 2012; 22: 1724-34.
38. Vinh-Hung V, Everaert H, Lamote J, et al. Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer. Eur J Nucl Med Mol Imaging, in press.